Biomimetic nanoplasmonic sensor for rapid evaluation of neutralizing SARS-CoV-2 monoclonal antibodies as antiviral therapy
Batool, Razia (Institut Català de Nanociència i Nanotecnologia)
Soler Aznar, Maria (Institut Català de Nanociència i Nanotecnologia)
Colavita, Francesca (National Institute for Infectious Disease "L. Spallanzani")
Fabeni, Lavinia (National Institute for Infectious Disease "L. Spallanzani")
Matusali, Giulia (National Institute for Infectious Disease "L. Spallanzani")
Lechuga, Laura M (Institut Català de Nanociència i Nanotecnologia)

Fecha:	2023
Resumen:	Monoclonal antibody (mAb) therapy is one of the most promising immunotherapies that have shown the potential to prevent or neutralize the effects of COVID-19 in patients at very early stages, with a few formulations recently approved by the European and American medicine agencies. However, a main bottleneck for their general implementation resides in the time-consuming, laborious, and highly-specialized techniques employed for the manufacturing and assessing of these therapies, excessively increasing their prices and delaying their administration to the patients. We propose a biomimetic nanoplasmonic biosensor as a novel analytical technique for the screening and evaluation of COVID-19 mAb therapies in a simpler, faster, and reliable manner. By creating an artificial cell membrane on the plasmonic sensor surface, our label-free sensing approach enables real-time monitoring of virus-cell interactions as well as direct analysis of antibody blocking effects in only 15 min assay time. We have achieved detection limits in the 10 TCID50/mL range for the study of SARS-CoV-2 viruses, which allows to perform neutralization assays by only employing a low-volume sample with common viral loads. We have demonstrated the accuracy of the biosensor for the evaluation of two different neutralizing antibodies targeting both Delta and Omicron variants of SARS-CoV-2, with half maximal inhibitory concentrations (IC) determined in the ng/mL range. Our user-friendly and reliable technology could be employed in biomedical and pharmaceutical laboratories to accelerate, cheapen, and simplify the development of effective immunotherapies for COVID-19 and other serious infectious diseases or cancer.
Ayudas:	Agencia Estatal de Investigación PGC-2018-099870 European Commission 101003544 Ministerio de Ciencia e Innovación PRE2019-089357 Ministerio de Ciencia e Innovación RYC2020-029015-I Ministerio de Ciencia e Innovación SEV-2017-0706 European Commission 871029
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Publicado en:	Biosensors & bioelectronics, Vol. 226 (April 2023) , art. 115137, ISSN 1873-4235

DOI: 10.1016/j.bios.2023.115137
PMID: 36796306

9 p, 4.8 MB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias > Institut Català de Nanociència i Nanotecnologia (ICN2)
Artículos > Artículos de investigación
Artículos > Artículos publicados